Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)

Recruiting

• Conditions: Sepsis; Septic Shock; Bacteremia; Antibiotic Side Effect; Antibiotic Resistant Infection; Infection, Bacterial; Critical Illness; Adult Children
• Interventions: Other: Drug Infusion Pump Monitoring

• Registration Number: NCT05950984
• Lead Sponsor: St George's, University of London

Brief Summary

Getting the right dose of antibiotic promptly is an important part of treating infections. Unfortunately, when an infection is severe (sepsis) the body changes how it processes antibiotics. Consequently, some people with severe infection retain antibiotics for too long (risking adverse effects), whilst others excrete antibiotics too quickly (risking under-treatment).

Mathematical models can help researchers understand drug handling variability (known as pharmacokinetics) between people. These models require very accurate information about drug administration and drug blood concentration timings. Researchers usually rely on someone recording these timings, but recording errors can make models inaccurate.

We would like to understand if using data from routinely used electronic drug infusion devices (recording the exact time of administration) can improve the accuracy of pharmacokinetic models. We intend to investigate this with an antibiotic (vancomycin) that clinicians already routinely monitor blood concentrations for. Adults and children treated at St George's Hospital intensive care units will be invited to participate in the study which will last for 28-days within a 14-month period. Participants will donate a small amount of extra blood and provide researchers access to their clinical data. Blood will be taken at special times during vancomycin treatment from lines placed as part of standard treatment, minimising any pain or distress. There will be no other changes to patient's treatment.

In the future, data from this study might help change the way we dose antibiotics. The National Institute for Health and Care Research and Pharmacy Research UK are supporting the study with funding.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-29
• Study First Submitted QC: 2023-07-10
• Study First Posted: 2023-07-18
• Study Start: 2023-10-30
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-10
• Last Update Posted: 2024-01-11
• Primary Completion: 2024-07
• Study Completion: 2024-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Admitted to either adult or paediatric intensive care unit (ICU) and receiving intravenous vancomycin (continuous or intermittent infusion only), to prevent or treat a clinical infection
• Informed consent form signed by participant/parent/legal guardian/legal representative (as determined by age group/capacity, consent may be retrospective) or signed informed personal/nominated consultee declaration
• Age from 1-day since birth

Read More

Exclusion Criteria

• Previous enrolment into this study
• Treating clinician feels participant unlikely to survive beyond 48-hours from enrolment or treatment has been withdrawn for reasons of palliation
• Absence of in-dwelling vascular access from which samples may be drawn or removal of in-dwelling access prior to retrieval of a 3rd blood sample (for assay of vancomycin concentration)
• Non-continuous renal replacement (i.e. intermittent haemodialysis/ peritoneal dialysis)
• Hypersensitivity or allergies to vancomycin, its excipients, or the infusion fluid
• Treatment outside an ICU area

In paediatrics:

• Required blood sampling exceeds 3% of total blood volume in a four-week period or 1% at any single time (European Medicines Agency, 2009)
• Where there is disagreement between child consent/assent and parental/ legal guardian consent/assent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Critically Ill Adults and Children	Drug Infusion Pump Monitoring	Adults and children from 1-day old admitted to a critical care unit.

Primary Outcome Measures

Name	Time	Method
Objective Function Value	Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin	Pharmacokinetic model fit determined quantitively by Objective Function Value (2.log likelihood) using vancomycin administration time data recorded by patient's bedside drug infusion devices compared to manually recorded data

Secondary Outcome Measures

Name	Time	Method
Participant Vancomycin Volume of Distribution	Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin	Calculation of participant's vancomycin volume of distribution (litres) using non-linear mixed effects modelling methods from obtained non-protein bound and total vancomycin concentrations and patient's drug infusion device obtained administration time data
Participant 24-hour AUC:MIC Ratio	Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin	Calculation of the area under the 24-hour non-protein bound and total vancomycin concentration AUC/bacterial minimum inhibitory concentration (MIC) ratio using an empiric MIC of 1mg/L or MIC of obtained isolates (if available) using trapezial rule or vancomycin dose and calculated clearance
Participant Vancomycin Clearance	Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin	Calculation of participant vancomycin clearance (litres/hour) using non-linear mixed effects modelling methods using obtained non-protein bound and total vancomycin concentrations and participant's drug infusion device derived administration time data
Participant 24-hour Area Under the Vancomycin Concentration Time Curve (AUC)	Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin	Calculation of participant's AUC (milligrams.hour/litre) using obtained non-protein bound and total vancomycin concentrations and participant's drug infusion device derived administration time data

Trial Locations

Locations (1)

St Georges University Hospitals NHS Foundation Trust; 🇬🇧 London, United Kingdom